Could a gut Bug's protein help control blood sugar?
NCT ID NCT06923839
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether a peptide made by a common gut bacterium, RUCILP, can affect blood sugar and hunger-related hormones in 15 healthy men. Participants receive either the peptide or a placebo through a tube in the small intestine. The study aims to see if RUCILP changes levels of key hormones like GLP-1 and insulin, which are important for metabolism.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- RUCILP (a gut bacterial peptide)
- What this could lead to
- If it works, this could point toward a new way to manage blood sugar or appetite using a natural gut molecule.
- What could go wrong
- This is a very early Phase 1 trial with only 15 healthy men. It tests short-term effects, not long-term safety or benefit. Results may not apply to people with health conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2025
- Expected to finish
-
Apr 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 35 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 18 and 35 years * Self-reported good health * Caucasian * Normal body mass index (18.5 to \<25) Exclusion Criteria: * Any known disorder/disease that could interfere with study results or is seen as compromising to the study (as assessed by the investigator), for example diabetes, cancer or cardiovascular or kidney disease. * Use of any daily medication as well as p.r.n. (pro re nata; not taken regularly) medication that cannot be discontinued during the trial * Use of antibiotics during the recent three months * Acute or chronic gastrointestinal symptoms * Lactose intolerance * Smoking * Alcohol or drug abuse * Use of creatine as dietary supplement during study period * Plasma creatinine concentration above the normal range (\>105 μmol/L) * Known significant liver disease or plasma ALAT concentration ≥ 3 × normal value * Values for hemoglobin, leukocytes, or thrombocytes outside of the normal ranges
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy male adults are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gentofte Hospital
Hellerup, 2900, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.